BGB-3111-213

Completed

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Beigene Study ID info

BGB-3111-213

ClinicalTrials.gov ID info

Clinical Drug Trials ID info

CTR20170965

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

Study Documents

Study Protocol Statistical Analysis Plan

You are now leaving BeiGene Australia


BeiGene provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained byBeiGene Australia, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.

You will be redirected to

Click the link above to continue or CANCEL